British pharmaceutical company GlaxoSmithKline and Germany’s CureVac announced Wednesday that they will collaborate on a new generation of vaccines against new variants of the coronavirus.
The announcement comes as public health experts from around the world express concern about mutations in the virus that could make existing vaccines less effective.
“The rise of emerging variants with the potential to reduce the efficacy of the first generation of COVID-19 vaccines requires acceleration of efforts to develop vaccines against new variants to stay one step ahead of the pandemic,” said the companies. it’s a statement.
“This new generation of vaccines for COVID-19 could be used either to protect the population that has not been vaccinated before or as a booster in the event that the immunity against COVID-19 obtained in the initial vaccination is reduced with the time, ”they added.
Additionally, GSK said it will help CureVac manufacture up to 100 million doses of the potential vaccine it is working on this year.
–
